2004 Fiscal Year Final Research Report Summary
Studies on new molecular therapeutic approach for radiation pneumonitis
Project/Area Number |
15390256
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Respiratory organ internal medicine
|
Research Institution | The University of Tokushima |
Principal Investigator |
SONE Saburo The University of Tokushima, 大学院・ヘルスバイオサイエンス研究部, 教授 (40145024)
|
Co-Investigator(Kenkyū-buntansha) |
TANI Kenji 徳島大学, 大学院・ヘルスバイオサイエンス研究部, 助教授 (70207166)
|
Project Period (FY) |
2003 – 2004
|
Keywords | radiation pneumonitis / CD13 / aminopeptidase N / macrophages / bestatin |
Research Abstract |
The cell-surface glycoprotein CD13 first identified in leukocytes of the myeloid series is identical to aminopeptidase N (EC 3.4.11.2). In this study, we examined here the significance of CD13/aminopeptidase N in radiation-induced pulmonary fibrosis using an animal model. The activity of aminopeptidase in bronchoalveolar lavage fluid (BALF) was significantly higher in rats with radiation pneumonitis at 2-4 weeks after the irradiation than in control rats. CD13/aminopeptidase N protein, which has a molecular mass of approximately 150 kD, was detectable in alveolar macrophages (AM) from rats with radiation pneumonitis at higher levels than in those from control rats. Higher chemotactic activity for lymphocytes was detected in the BALF from rats with radiation pneumonitis than that from control rats, and the activity was significantly decreased by the treatment with bestatin, a specific aminopeptidase inhibitor, indicating that CD13/aminopeptidase N expressed in AM may have a role in T lymphocyte involvement in radiation pneumonitisn and the pathogenesis of alveolitis in this disorder. Our results suggest that bestatin may be useful for the treatment of radiation pneumonitis. We are now testing the effect of oral administration of bestatin in animal model of radiation pneumonitis.
|
Research Products
(16 results)